Skip to content

Study · Not a test of the peptide alone · 2021

1 result

Structural effects driven by rare point mutations in amylin hormone, the type II diabetes-associated peptide.

Mendes WS, Franco OL, Alencar SA, Porto WF

Biochimica et biophysica acta. General subjects25 May 2021Cited by 3 (Europe PMC)

PMID34044067 (opens in a new tab)DOI10.1016/j.bbagen.2021.129935 (opens in a new tab)PepBankPUB-34044067
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 01Computer modelNot a test of Pramlintide (Symlin) aloneIn silicoMechanism

    In computational comparisons with pramlintide, maintenance of the second α-helix might relate to amylin aggregation potential.

    In plain wordsIn computer analyses comparing amylin with pramlintide, preservation of the second helix might relate to aggregation potential.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableSecond α-helix and aggregation potential
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Furthermore, comparative analyses with pramlintide, an amylin drug analogue, allowed us to infer that second α-helix maintenance may be related to the aggregation potential.
    1 context sentence
    Summary · context
    The analyses were performed by means of aggrescan server, SNP functional effect predictors, and molecular dynamics.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.